STUDY QUESTION: Is the Transmembrane BAX Inhibitor Motif-6 (TMBIM6) involved in the molecular mechanism by which cisplatin causes reproductive toxicity?
Introduction
Platinum derivative drugs play an important chemotherapeutic role in the treatment of solid tumors. Among them, cisplatin (cis-diamminedichloroplatinum) is the most commonly used (Pabla and Dong, 2008) . However, despite its curative effects on solid tumors, cisplatin shows nephrotoxicity, anaphylaxis, ototoxicity, and bone marrow suppression (Hartmann et al., 2000; Hartmann and Lipp, 2003) . Recently, side effects of cisplatin have been observed in testis (Ciftci et al., 2011) . Testosterone production capacity is highly decreased after exposure to cisplatin due to the generation of reactive oxygen species (ROS) as a result of impaired mitochondrial oxidative phosphorylation and through the generation of DNA adducts (Marullo et al., 2013) .
The steroidogenic activity of cells is regulated by a protein called steroidogenic acute regulatory protein (StAR) . StAR mediates the rate-limiting step in the transfer of cholesterol from the outer mitochondria to the inner mitochondrion (Rone et al., 2009) . Increased activity of StAR protein transports cholesterol into mitochondria, where it is further metabolized to pregnenolone by cytochrome P450 11A1 (CYP11A1). The pregnenolone is transferred from mitochondria to the endoplasmic reticulum (ER) and is converted to progesterone by the action of 3β-hydroxysteroid dehydrogenase Δ5-Δ4-isomerase (3β-HSD). The progesterone is finally converted to testosterone by 17 β-hydroxysteroid dehydrogenase (HSD17β6) (Stocco, 2001 ). An increase in ROS induced by cisplatin is one cause of a decrease in StAR, whereas ER-localized heme oxygenase-1 (HO-1) inhibits ROSinduced apoptosis (Diemer et al., 2003) . HO-1 activity has been also reported to be linked to the StAR protein (Shiraishi and Naito, 2005) .
ER promotes the synthesis of new proteins and protein folding and post-translational modification. Disturbance in the usual activities of the ER leads to ER stress (Yadav et al., 2014) . ER stress can be generated by oxidative stress due to chemicals, changes in calcium storage, glycosylation inhibition, nutrient deprivation and pathogen infection (Wang and Kaufman, 2012) . Increased ER stress leads to defects in the synthesis of steroidogenic enzymes (Park et al., 2013) . To control ER stress, the unfolded protein response (UPR) is activated, which in turn induces IRE1α, PERK and ATF6α signaling. Chaperone proteins such as glucose-regulated protein Grp78, calreticulin, calnexin and protein disulfide isomerase (PDI) also contribute to the UPR process. Among them, PDI, an important ER catalyst, is involved in disulfide bond formation (Bulleid, 2012) and the regulation of thiol/disulfide exchange. A decrease in PDI activity and binding to client proteins leads to an inability of PDI to form disulfide bonds in the ER, resulting in increased ER stress (Bhandary et al., 2012) . ROS have been suggested to induce excessive post-translation oxidation through post-translational modification of PDI and carbonylation in the ER (Kenche et al., 2013; Lee et al., 2016) . Cisplatin-induced ROS production might be linked to the alteration of the redox state of PDI and its hypercarbonylation impairing ER protein folding, leading to ER stress.
The antiapoptotic protein transmembrane BAX inhibitor motif-6/ Bax inhibitor-1 (TMBIM-6/BI-1) is an ER stress inhibitor (Chae et al., 2004) . Cisplatin-induced ER stress (Mandic et al., 2003) leads to defects in folding and maturation of ER-localized steroidogenic enzymes. A defect in the maturation of ER-localized steroidogenic enzymes leads to a decrease in testosterone formation. As HO-1 activity is high in the presence of TMBIM6 (Lee et al., 2007) , we hypothesized that TMBIM6 might have protective activity against ROSinduced testicular toxicity and allow the production of more testosterone in the presence of ER stress.To investigate the protective role of TMBIM6 against ER stress and the associated alteration of steroidogenesis and the underlying mechanism, we examined cisplatin-induced testicular toxicity in a Tmbim6 knockout mouse model and Tmbim6-overexpressing Leydig cells.
Materials and Methods

Reagents
Cisplatin (Cis), N-ethylmaleimide (NEM), Rapamycin and Hoechst 33342 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against HO-1, and VDAC1 were obtained from Abcam. Antibodies against Nrf2, β-actin, StAR, 3β-HSD, GRP78, and eIF2α were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against CYP11A1, p-AKT, AKT, CHOP, histone H3 and p-eIF2α were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody against PDI was obtained from Enzo Life Sciences (Farmingdale, NY, USA). Pregnenolone measurement kit (Immuno-biological Laboratories, MN, USA) and testosterone ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA) were used in this study.
Cell culture
TM3 Leydig cells from an immortalized mouse testis cell line were obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea). TM3 Leydig cells were stably transfected with pcDNA™3.1/Hygro(+) and pcDNA™3.1/Hygro(+)-Tmbim6 plasmids using the lipofectamine3000 transfection reagent (Invitrogen). The cells were cultured for 2 weeks in 100 μg/mL hygromycin (Invitrogen) and then grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% v/v fetal bovine serum (FBS) supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin and incubated at 37°C in a humidified atmosphere containing 5% CO 2 .
Animal experiments
Mice (C57BL/6J) were housed in groups of five animals at 21 ± 1°C and 55 ± 5% humidity under a 12 h/12 h light/dark cycle. Mice were maintained in specific pathogen-free housing and were cared for in accordance with the regulations of the Care and Use of Laboratory Animals guide of Chonbuk National University with approval from the Institutional Animal Care and Use Committee of Chonbuk National University laboratory animal center (CBNU 2016-70) . The TMBIM6 +/+ wild-type (WT) and TMBIM6 −/− knockout (KO) mice used in this study were described previously (Chae et al., 2004) . In animal experiments, to evaluate the effect of cisplatin, mice were divided into four groups (n = 7 each): TMBIM6 +/+ and TMBIM6 −/− cisplatin treatment groups which received a single intraperitoneal injection of 30 mg/kg body weight of cisplatin on the first day as acute models, and TMBIM6 +/+ and TMBIM6 −/− vehicle control groups received a saline. The cisplatin dose used was based on single-dose intravenous cisplatin therapy frequently applied to cancer patients. The cisplatin dose given (100 mg/m 2 ) is based on body surface area but is equivalent to 28-30 mg/kg (Chang et al., 2013; Mitazaki et al., 2013) . For testis experiments, the left testis (n = 7, each) was used for immunoblotting, RNA expression, PDI redox and DNP experiments, and the other testis was used for the other experiments (n = 7, each). Animals were anesthetized with ketamine on the third day, and blood and testis tissue samples were collected.
Lentivirus-mediated gene transfer in vivo
For lentivirus-mediated gene transfer in vivo, Tmbim6 KO mice were infected via a single injection of purified 1.0 × 10 9 virus particle (Genenmed Inc., Seoul, Korea) in a volume of 50 μl (diluted in saline) into the testis, as previously described (Ogawa et al., 1997) . After 2 days of infection with the virus, mice were treated with cisplatin or saline for the subsequent 3 days. Mice were sacrificed, and testis samples were collected and stored at −80°C for subsequent analysis.
Immunohistochemistry and immunofluorescence
We used formalin fixed paraffin and Tissue-Tek OCT compound embedded testis tissues for immunohistochemistry and immunofluorescence staining, respectively. The tissue samples were stained with antibodies as previously described (Chae et al., 2004) . Serial 5-μm thick sections were prepared, blocked with 5% serum after antigen retrieval, and incubated at 4°C overnight with one of the following primary antibodies. Immunostaining was visualized with 3,3'-diaminobenzidine (DAB) and sections were counterstained with hematoxylin and eosin.
Measurement of testosterone
Blood samples were centrifuged for 15 min at 2000g using a bench centrifuge, and plasma was stored at 4°C for testosterone assay using a commercially available Testosterone ELISA kit (Enzo, USA) in accordance with the manufacturer's instructions.
Quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen) and reverse transcription was performed using a superscript III first strand synthesis kit (Invitrogen) according to the manufacturer's instructions, which were determined by qPCR. The primer sequences and reaction conditions are listed in Supplementary Table SIV.
Immunoblot analysis
Cells or tissue samples were lysed with RIPA buffer (GenDEPOT, USA) containing a protease inhibitor and phosphatase inhibitor cocktail (SigmaAldrich) for 30 min on ice, followed by centrifugation at 10 000g for 20 min at 4°C. The resulting supernatants were collected and used as protein extracts. Protein extracts (30 μg) were separated on polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Bio-Rad, USA) for 1 h. After 1 h in blocking buffer containing 5% w/v non-fat dry milk (Bio-Rad, USA) and 0.05% v/v Tween 20 in Tris-buffered saline (TBS-T), the membrandes were probed overnight at 4°C with the relevant primary antibodies. The membranes were washed three times with TBS-T for 30 min, and incubated with secondary antibodies at room temperature for 1 h, and washed three times with TBS-T for 30 min. The protein bands were detected using an enhanced electrochemiluminescence (ECL) Detection System (Thermo Fisher Scientific, USA), and immunoreactive bands were visualized using an LAS-3000 system (Fuji Film, Japan). Band intensities were measured and quantified using ImageJ software (National Institutes for Health).
Electron microscopy
Testis tissues were fixed by a conventional method (2% glutaraldehyde and 2% formaldehyde in 0.05 M sodium cacodylate buffer, pH 7.2) (Nishida et al., 2009; Park et al., 2011a) . Fixed samples were embedded in Spurr's resin, and thin sections (80 nm) were cut and stained with uranyl acetate and lead citrate for observation under a transmission electron microscope (H7650, accelerating voltage 100 kV, Hitachi) at the Center for University-wide Research Facilities (CBNU).
PDI redox state and high-molecular-weight protein complex formation in the testis samples Procedures were performed as described previously (Molteni et al., 2004) . Briefly, testis tissues were washed twice with ice-cold PBS supplemented with 20 mM N-ethylmaleimide (NEM) to protect the reduced disulfide bonds from further oxidation during lysis, lysed in lysis buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 0.5% v/v Triton X-100) for 30 min on ice, and cleared by centrifugation. The 50 μg of the total protein was separated on non-reducing polyacrylamide gels (no SDS, not boiled) at 50 V to distinguish between redox forms of PDI.
Detection of carbonylated PDI
For detection of carbonylated PDI, proteins (100 μg) were derivatized for 5 min using the OxyBlot kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. PDI was immunoprecipitated as described previously , resolved in non-reducing gels, and subjected to Western blot analysis with anti-DNP rabbit antibodies according to the OxyBlot kit instructions.
Heme oxygenase-1 activity
Heme oxygenase-1 activity was measured in isolated microsomes as previously described (Nath et al., 1992) . The samples were homogenized in phosphate buffer (pH 7.4), sonicated on ice, and centrifuged at 1000g for 10 min at 4°C. The resulting supernatants were centrifuged at 100 000g for 60 min at 4°C. The pellet was suspended in phosphate buffer (pH 7.0) containing 2 mM MgCl 2 and designated the microsome fraction. An aliquot of the microsomal fraction was added to a reaction mixture containing cytosol of the cells (2 mg of cytosolic protein), hemin (20 μM), glucose-6-phosphate (2 mM), glucose-6-phosphate-dehydrogenase (0.2 units), and NADPH (0.8 mM) and incubated at 37°C for 2 h in the dark. The bilirubin formed during incubation was extracted using chloroform. The change in optical density was measured at 464-530 nm. HO-1 activity was expressed as picomoles of bilirubin formed per h/mg of protein.
Detection of intracellular ROS levels
For the detection of ROS in cells, cells were incubated with 100 μM 2′,7′-dichlorofluorescein diacetate (DCF-DA) at 37°C for 30 min after treatment with cisplatin. The fluorescence intensity of 2',7'-dichlorofluorescein formed by a reaction between DCF-DA and intracellular ROS was analyzed by PAS flow cytometry (Partec, Münster, Germany) at excitation and emission wavelengths of 488 and 525 nm, respectively. For the detection of ROS in testis tissues, cryosection tissues slides were incubated with dihydroethidium (DHE) as biomarker of oxidative stress.
In situ hybridization
In situ detection of Tmbim6 transcripts in WT and tmbim6 −/− mouse testis samples was performed using the RNAscope assay kit (Advanced Cell Diagnostics, 310035, Newark, CA, USA), as described previously (Jang et al., 2013) . Briefly, 5-μm-thick paraffin-embedded tissue sections were deparaffinized, pretreated with heat and proteases and then hybridized with a target probe for the Tmbim6 gene. Next, an HRP-based signal amplification system was hybridized to the target probe before color development with 3,3'-diaminobenzidine tetrahydrochloride (Advanced Cell Diagnostics, 310035, Newark, CA, USA). Positive staining was defined as the presence of brown punctate dots in the nucleus and/or cytoplasm. The housekeeping gene Ubc (ubiquitin C) served as a positive control. The DapB gene, which is derived from a bacterial gene sequence, was used as a negative control.
Statistical analysis
All data are presented as the mean ± SEM of several independent experiments, as specified in the figure legends. Differences among the four groups in the animal and cell culture studies (in animal study: saline-treated WT, saline-treated KO, cisplatin-treated WT, and cisplatin-treated KO mice; in cell culture study: saline-treated vector TM3, cisplatin-treated vector TM3, saline-treated Tmbim6 TM3 and cisplatin-treated Tmbim6 TM3) were analyzed using one-way analysis of variance (ANOVA). Origin 8.0 software from OriginLab ® Corp (Northampton, MA, USA) and GraphPad
Prism 5.01 were used for statistical calculations. A P-value <0.05 was considered statistically significant.
Results
Tmbim6 protects testis against cisplatin toxicity
Expression of Tmbim6 was clearly detectable in the spermatogonia, Sertoli cells, Leydig cells, primary spermatocytes and spermatids in mouse testis, as examined by in situ hybridization (Fig. 1a) . after cisplatin treatment, the testicular weight in cisplatin-treated Tmbim6 KO mice was decreased to a significantly greater extent than in Tmbim6 wild type (WT) (Fig. 1b) , as was the serum testosterone concentration (Fig. 1c) . Consistent with these findings, testosterone production was not significantly changed after cisplatin treatment in Tmbim6-overexpressing TM3 cells whilst it showed a dose dependent decrease in vector-only transfected TM3 cells (Supplementary Fig. S1a and b) . Histopathologic analysis of seminiferous epithelium showed that cisplatin-treated Tmbim6 KO mice had greater testicular damage, vacuole formation, and decrease in germ cells with wide lumen compared with cisplatin-treated Tmbim6 WT mice (Fig. 1d , Supplementary  Table SI) . After cisplatin treatment, TUNEL-positive staining was increased significantly more in the Tmbim6 KO testis compared with the treated Tmbim6 WT testis (Fig. 1e) . The Tmbim6-overexpressing TM3 cells also showed more resistance to cisplatin-induced toxicity compared with only vector-transfected TM3 cells ( Supplementary  Fig. S1c -e). After cisplatin treatment the ROS level was increased significantly more in the testis of Tmbim6 KO mice, compared with WT mice (Fig. 1f) . Ultrastructure analysis of sperm revealed a wellorganized structure in both non-treated Tmbim6 WT and KO mice (Fig. 2) . After cisplatin treatment, Tmbim6 KO spermatozoa showed more abnormal mitochondria structure, more pronounced loss of microtubules, greater vacuolation in the sperm plasma membrane and greater degradation of the acrosome compared with Tmbim6 WT (Yao et al., 2002; Zhou et al., 2011) . The Golgi bodies, which are important for the formation of the acrosome, were more affected by cisplatin in the Tmbim6 KO condition compared with the WT. Consistent with these findings, the weights of seminal vesicles and epididymis plus vas deferens, and sperm count in the cisplatintreated Tmbim6 KO testis were significantly more decreased than in Tmbim6 WT testis (Supplementary Table SII) . Together, these findings suggest that Tmbim6 has a protective role against cisplatininduced testicular toxicity.
Tmbim6 protects against cisplatin-induced testicular toxicity through pAKT-Nrf2-HO-1 signaling
To understand the Tmbim6-induced protective mechanism against cisplatin, we examined Akt-Nrf2-HO-1 signaling. First, after cisplatin treatment the level of pAkt was increased significantly more in Tmbim6 WT testis compared with KO testis (Fig. 3a and b) . The downstream expression of HO-1 protein and mRNA, and nuclear localization of Nrf2 were also more highly increased in the cisplatintreated WT testis compared with treated KO testis ( Fig. 3a-c) . In immunostaining analysis, HO-1 expression was also highly increased in Leydig cells, and slightly increased in Sertoli cells after cisplatin treatment (Fig. 3d) . Moreover, the level of p-Akt, HO-1, and nuclear expression of Nrf2 were more highly increased in Tmbim6-overexpressing TM3 Leydig cells (Tmbim6 TM3 cells) than vectortransfected TM3 cells (vector TM3 cells) (Fig. 3e , Supplementary  Fig. S2 ). HO-1 activity was also increased to a greater extent in cisplatin-treated Tmbim6 TM3 cells than in the treated vector TM3 cells (Fig. 3f) . The testosterone level was relatively highly maintained in Tmbim6 WT mice compared to Tmbim6 KO mice under the constitutive activation of p-AKT by rapamycin ( Supplementary Fig. S3a and b) . Consistent with these observations, cisplatin-induced ROS accumulation was also significantly inhibited in the presence of Tmbim6 (Fig. 3g) . These data indicate that cisplatin-associated p-Akt, Nrf2 and HO-1 signaling is highly enhanced in the presence of Tmbim6.
Tmbim6 maintains expression of testosterone synthesis-associated proteins in cisplatin-treated conditions
The expression of StAR was decreased significantly more in the cisplatin-treated Tmbim6 KO mice compared with the treated Tmbim6 WT mice ( Fig. 4a and b) (Diemer et al., 2003) . Cyp11a1 was not affected in Tmbim6 WT testis after cisplatin treatment, whereas it was significantly decreased in the treated KO testis. Moreover, expression of StAR and Cyp11a1 was significantly decreased in the treated vector TM3 cells, while that expression was maintained at a high level in cisplatin-treated Tmbim6 TM3 cells ( Fig. 4c and d) . However, in a quantitative RT-PCR analysis, the mRNA expressions of StAR and Cyp11a1 were not significantly different between the treated Tmbim6 WT and the KO testis ( Supplementary Fig. S4a and b) . Markedly, the expression of StAR was rapidly decreased after cisplatin treatment, a representative phenomenon for protein degradation such as ubiquitination (Li et al., 2004; Zhang et al., 2015) . Expectedly, the ubiquitination of StAR was increased in cisplatin-treated control TM3 cells compared to the treated Tmbim6 TM3 cells (Fig. 4e) . The other steroidogenic enzyme, Cyp11a1 was also confirmed to be ubiquitinated. Treatment with cisplatin inhibited mitochondrial localization of StAR, whereas the mitochondrial localization was relatively stable in the cisplatin-treated TMBIM6-overexpressing cells, compared with the treated vector expressing cells ( Supplementary Fig. S5 ). Consistent with these findings, although cisplatin did not affect serum cholesterol it decreased serum pregnenolone concentration but to a greater extent in Tmbim6 KO mice than in WT ( Fig. 4f and g ), suggesting that TMBIM6 protects steroidogenic activities in the presence of cisplatin, The endogenous housekeeping gene UBC and the bacterial gene dapB were used as positive and negative markers for in situ hybridization, respectively. Spermatogonia (Sg), Sertoli cells (S), Leydig cells (L), Spermatocytes (Sp) and Spermatids (St). Scale bars = 20 μm. Tmbim6 WT and KO mice were injected with 30 mg/kg cisplatin or normal saline (n = 7/group). Three days later, testicular weights (b), serum concentration of testosterone (c), hematoxylin and eosin (H&E) staining (d), Tunnel staining (e), and dihydroethidium (DHE) staining (f) were analyzed as described in Materials and Methods. Black arrowheads indicate vacuole formation. Scale bars = 100 μm. Data were normalized to the saline-treated Tmbim6 WT group. oneway ANOVA, *P < 0.05, **P < 0.001 and ***P < 0.0001.
and that StAR signaling contributes to the TMBIM6-associated steroidogenic activities.
TMBIM6 controls ER folding capacitance, thus regulating ER stress in cisplatin-treated condition
Expression of 3β-HSD was significantly more decreased in the cisplatin-treated Tmbim6 KO mice than the treated Tmbim6 WT mice ( Fig. 5a and b) . In the presence of cisplatin, 3β-HSD mRNA expression was obviously decreased, although the difference between Tmbim6 WT and KO testis were not significant ( Supplementary  Fig. S4c ). Expectedly, levels of the ER stress marker proteins Grp78, Chop and p-eIf2α were prominently increased in cisplatin-treated Tmbim6 KO testis, compared with the treated Tmbim6 WT testis (Fig. 5c, Supplementary Fig. S6 ). The formation of high-molecular weight complexes (HMWCs) by PDI was also significantly increased in Tmbim6 KO, compared with Tmbim6 WT testis (Fig. 5d ). These data indicate that PDI binds to the high-molecular weight proteins, leading to a decrease in disulfide bond formation, especially in the Tmbim6 knockout condition. In TMBIM6-overexpressing TM3 cells, PDI-bound HMWC formation was reduced compared with control TM3 cells (Fig. 5e) . PDI was highly carbonylated in cisplatin-treated Tmbim6 KO relatively to Tmbim6 WT testis (Fig. 5f ), indicating that the presence of TMBIM6 decreases the level of ROS and protein oxidation in cisplatintreated conditions.
Tmbim6 maintains stereogenic enzyme activity in a cisplatin-treated condition through a pAKT-Nrf2-HO-1 axis
The role of Tmbim6 in the testis was further examined through lentiviral Tmbim6 testicular seminiferous infection into Tmbim6 KO mice. Compared with the GFP-infected control, testicular Tmbim6 expression had little effect on testosterone in the absence of cisplatin but conferred significant resistance to the testosterone lowering effect of the drug (Fig. 6a) . Expression of Tmbim6 increased the level of phosphorylated Akt and expression of HO-1 before and after cisplatin treatment ( Fig. 6b and c) . Under control conditions infection of Tmbim6 had little effect on the expression of StAR, 3β-HSD and Cyp11a1 but conferred significant resistance against cisplatin ( Fig. 6b  and c) . In immunostaining analysis, HO-1 expression was also increased in the cisplatin-treated or non-treated Tmbim6 overexpression system (Fig. 6d) . These data suggest that Tmbim6-protective signaling against cisplatin includes Akt-HO-1 signaling.
Discussion
In this study, we explored the protective activities of TMBIM6 in the testis against cisplatin treatment. TMBIM6 protects against cisplatininduced testicular toxicity through the regulation of ROS matabolism through Nrf2 and related heme oxygenase-1. The presence of TMBIM6 also modulates cisplatin-induced ER folding disturbance and ER stress, maintaining a relatively high level of testosterone after cisplatin treatment compared with the Tmbim6 KO condition. Cisplatin treatment significantly decreased the steroidogenic enzymes StAR and 3β-HSD, whereas the presence of TMBIM6 recovered the decreased endocrine mechanism through the control of intra-ER resident HO-1 expression and ER redox balance. We showed that cisplatin-induced signaling pathways including p-AKT, Nrf2 and HO-1 were down-regulated in the absence of TMBIM6. Cisplatin-induced ROS are compensated with endogenous antioxidant mechanisms including HO-1 (Jiang et al., 2006; Jung et al., 2014) . In this study, the absence of TMBIM6 seems to disturb the compensatory antioxidant system of HO-1 and the Akt-Nrf2-HO-1 axis signaling (Fig. 3a) , showing ROS accumulation with decreased testosterone ( Fig. 1f and c) . PI3K-Akt serves as an important signaling pathway in the induction of HO-1 (Park et al., 2011b) . The increase in HO-1 promoter activity is also preceded by an increase in Akt phosphorylation, whereas Akt knockdown with siRNA almost completely suppressed HO-1 expression in response to H 2 O 2 (Brunt et al., 2006) . This study also suggests the involvement of ROS in the cisplatin-associated testicular structure alteration, showing greater testicular damage, vacuole formation and decrease in germ cells with a wide lumen in the tmbim6-KO compared with WT condition (Figs 1d Figure 2 TMBIM6 protects against cisplatin-induced abnormal alteration of testis structure. Tmbim6 WT and KO mice were injected with 30 mg/kg cisplatin or normal saline. Three days later, electron microscopy analysis was performed. Scale bars = 1 μm. Mt, mitochondria; ODF, outer dense fiber; Ax, Axonema; Ac, acrosome; GB, Golgi bodies. and 2e). In the cisplatin-induced ROS accumulation and its testicular toxicity model, The HO-1-linked mechanism is strongly implicated to explain the protective effect of TMBIM6 against cisplatin as summarized in Fig. 6e . With regard to the endogenous expression of HO-1 in the presence of TMBIM6, there has been some debate (Lisbona et al., 2009) . To better clarify the endogenous expression of HO-1, immunoblotting was performed in MEF cells and Tmbim6-overexpressing cells, showing more significant expression of HO-1 in non-treated Tmbim6 mouse embryo fibroblasts and in TMBIM6-overexpressing TM3 cells compared with each counter group ( Supplementary Fig. S7a and b) . The AKT-Nrf2-HO-1 axis might contribute to the preservation of testicular structure, which is disrupted in the cisplatin-treated Tmbim6 knockout condition.
The expression of StAR was significantly decreased after cisplatin treatment, especially in Tmbim6 KO testis (Fig. 4a) . Similarly, the expression of CYP11A1 and 3β-HSD was also decreased in Tmbim6 Immunoblotting with antibodies against p-AKT, AKT, HO-1 and β-actin for whole cell lysates and against Nrf2 or histone for nuclear fraction (e) was performed (n = 3). Vector and TMBIM6-stable TM3 cells were treated with 20 μM cisplatin for 24 h, and HO-1 activity was measured as described in Materials and Methods (n = 3) (f). Vector and TMBIM6 TM3 cells were treated with 20 μM cisplatin for 12 h and incubated with 2',7'-dichlorofluorescein diacetate (DCF-DA) for 30 min following DCF-DA analysis by flow cytometry (n = 3) (g). Data normalized to the saline-treated Tmbim6 WT group. One-way ANOVA, *P < 0.05, **P < 0.001 and ***P < 0.0001.
KO, indicating relatively low production of testosterone and pregnenolone in the absence of TMBIM6 (Figs 1c and 4e) . The mRNA levels of StAR, CYP11A1 and 3β-HSD showed no difference between cisplatintreated Tmbim6 WT and Tmbim6 KO (Fig. S4) . It seems likely that translational modification contributes to TMBIM6-associated maintenance of testosterone production even in the presence of cisplatin. (n = 7/group). Three days later, immunoblotting of testis tissues and mitochondrial (Mito) fraction with the indicated antibodies (a) and the quantification analysis of the indicated proteins were performed (b). Vector and TMBIM6-stably transfected TM3 cells were treated with 20 μM cisplatin for the indicated times. Immunoblotting with antibodies against StAR or Cyp11a1 (c) and its quantification analysis (n = 3) (d) and immunoprecipitation (IP) with the StAR or Cyp11a1 antibody and the immunoblotting with Ubiquitin antibody (e) were performed in the cell lysates (n = 3). Pregnenolone (f) and cholesterol analysis (g) were performed from Tmbim6 WT and KO mice as described in Materials and Methods. Data normalized to the salinetreated Tmbim6 WT group. One-way ANOVA, *P < 0.05, **P < 0.001 and ***P < 0.0001. Figure 5 TMBIM6 regulates cisplatin-induced ER stress. Tmbim6 WT and KO mice were injected with 30 mg/kg cisplatin or normal saline (n = 7/ group). Three days later, immunoblotting with antibodies against 3β-HSD (a) and quantification analysis (b) were performed. Immunoblotting with antibodies against Grp78, Chop, p-eIF2α, eIF2α or β-actin was performed (c). Whole testis lysates were analyzed for the presence of PDI in HMWCs using non-reducing (upper) and reducing (lower) gels (d). Vector TM3 cells and Tmbim6 TM3 cells were treated with 20 μM cisplatin for 0, 2, 4, 8, 12 or 24 h. Whole cell lysates were analyzed for PDI in HMWCs using non-reducing gels, and immunoblotting with anti-PDI antibody was performed (n = 3) (e). Whole testis lysates were derivatized with DNPH. Immunoprecipitated PDI was run on a non-reducing gel and analyzed by immunoblotting using anti-DNP antibody (n = 3) (f). PDI, protein disulfide isomerase; HMWCs, high molecular weight complexes. Data normalized to the saline-treated Tmbim6 WT group. one-way ANOVA, *P < 0.05, **P < 0.001 and ***P < 0.0001.
For folding of these steroidogenic proteins, ER folding capacitance represented by PDI and its related redox-coupled cycles are essential (Gidalevitz et al., 2013) . This study suggests that the ER stressmediated reduction in steroidogenic protein expression is related to dysfunctional PDI chaperone activity, a fundamental system in assisting protein folding . The unspecified folding proteins associated with the chaperone protein PDI were clearly accumulated as an aggregated form, especially in the Tmbim6 KO mice (Fig. 5d) , indicating that the Tmbim6 KO condition disrupts function of the chaperones and isomerases such as PDI. Carbonylated proteins were also highly associated with PDI, especially in the Tmbim6 KO mice (Fig. 5f) , suggesting that the majority of oxidized PDI resides within the HMWC fraction in association with client proteins, rather than releasing these proteins to their destinations. This study shows reduced/altered function of protein folding capacity, especially in the cisplatin-treated Tmbim6 KO condition. Throughout this study, cisplatin-induced ER stress is shown to be linked with PDI alterations and the stressassociated ROS accumulation during the steroidogenic protein folding/secretion processes, which are regulated by TMBIM6.
TMBIM6 is highly expressed in several cancers including prostate, breast and lung cancer (Grzmil et al., 2003 (Grzmil et al., , 2006 Lu et al., 2015) , but has not yet been studied in testicular cancer. To identify whether Figure 6 TMBIM6 restored stereogenic enzyme activity through pAKT-Nrf2-HO-1 signaling. Tmbim6 KO mice were infected with lentiviral-GFP and lentiviral-Tmbim6 in testis. After 1 day of viral infection, mice were intraperitoneally injected with 30 mg/kg cisplatin or saline (n = 7/group). Three days later, testosterone concentration in serum was measured (a). Immunoblotting with indicated antibodies (b) and quantification analysis (c) were performed.
Immunostaining with anti-HO-1 antibody was performed (d). Schematic diagram of the protective mechanism of Tmbim6 against cisplatin-induced testicular toxicity (e). Data normalized to saline-treated Tmbim6 WT group. one-way ANOVA, *P < 0.05, **P < 0.001 and ***P < 0.0001. testicular cancer expresses TMBIM6, we analyzed GSE8607 data from the open source GEO database of NCBI, in which TMBIM6 expression was significantly increased in testicular cancer (n = 40) compared with normal samples (n = 3) ( Supplementary Fig. S8 ). We also confirmed the expression of TMBIM6 in various cancer types through the Human Protein Atlas database. In RNA-seq data analysis from 17 cancer types, we found the expression of TMBIM6 in testicular cancer to be relatively lower than other tumor types, for example, ovarian and lung cancers, which show resistance against cisplatin chemotherapy (Supplementary Table SIII) , however, we also found the expression of TMBIM6 in testicular cancer to be higher than that of melanoma and similar to that of head and neck cancer. Although testicular cancer typically responds well to treatment with cisplatin, several studies about resistance to cisplatin-based chemotherapy in testicular cancer have been reported. Feldman and colleagues reported that cisplatin resistance was exhibited in up to 30% of patients with advanced germ cell tumors (Bagrodia et al., 2016) . Furthermore, head and neck cancers often demonstrate significant resistance to cisplatin, acquired through repeated treatment cycles or as an inherent characteristic of the cancer (Abuzeid et al., 2011) . In melanoma, cisplatin is frequently used in polychemotherapy regimens, but partial response is observed only iñ 10% (Soengas and Lowe, 2003) . The resistance to platinum-based chemotherapy is associated with a poor long-term survival rate. Cisplatin resistance also has implications for ongoing treatment since relatively minor increases in resistance necessitate significant dose escalations, which result in increased toxicity. Notably, cisplatin resistance in testicular cancer is believed to be multifactorial (Mayer et al., 2003) , which suggests that TMBIM6 is a factor of resistance through ROS inhibition, control of ER redox balance, and its associated ER stress. Further studies are necessary to determine the role of TMBIM6 in testicular cancer. In summary, cisplatin-induced ROS are linked to ER redox imbalance and ER stress, affecting steroidogenic protein maturation and ultimately decreasing testosterone levels. These responses are regulated by TMBIM6, which allows recovery of ER function through effective induction of HO-1 and finally contributes to the protection against cisplatin-induced testicular toxicity.
